Beacon Capital Management LLC has recently announced that it has increased stake in Evaxion Biotech A/S ADR (NASDAQ:EVAX) by 606.77%. After grabbing 48633.0 shares, the institutional investor is now in possession of 41752.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.18% having worth around $33362.0. Moreover, AE Wealth Management LLC increased its share by 48633.0 to have a control over 48633.0 shares. And Two Sigma Securities LLC raised its holdings to 15188.0 shares by acquiring 15188.0 shares or 0.06% of the stake.
Evaxion Biotech A/S ADR (EVAX) concluded trading on Wednesday at a closing price of $10.65, with 32.07 million shares of worth about $341.5 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -14.80% during that period and On Wednesday, January 24 the price saw a gain of about 113.43%. Currently the company’s common shares owned by public are about 2.41M shares.
Stock saw a price change of 38.98% in past 5 days and over the past one month there was a price change of 54.62%. Year-to-date (YTD), EVAX shares are showing a performance of 55.32% which decreased to -34.66% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.36 but also hit the highest price of $21.10 during that period. The average intraday trading volume for Evaxion Biotech A/S ADR shares is 33.85K. The stock is currently trading 50.81% above its 20-day simple moving average (SMA20), while that difference is up 48.11% for SMA50 and it goes to 2.52% higher than SMA200.
Beacon Capital Management LLC acquired 48633.0 shares of Evaxion Biotech A/S ADR having value of about $33362.0. Data submitted at the U.S SEC by Beacon Capital Management LLC revealed that the firm now holds 41752.0 shares in the company valued at close to $444658.8, or have control over 606.77% stake in the company. Evaxion Biotech A/S ADR (NASDAQ: EVAX) currently have 2.41M outstanding shares and institutions hold larger chunk of about 0.63% of that. Holding of mutual funds in the company is about 0.01% while other institutional holders and individual stake holders have control over 0.62% and — of the stake respectively.
The stock has a current market capitalization of $29.39M and its 3Y-monthly beta is at 0.02. It has posted earnings per share of -$9.44 in the same period. It has Quick Ratio of 2.81. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EVAX, volatility over the week remained 42.41% while standing at 17.17% over the month.
Analysts are in expectations that Evaxion Biotech A/S ADR (EVAX) stock would likely to be making an EPS of -$1.6 in the current quarter, while forecast for next quarter EPS is $0 and it is -$3.75 for next year. For the current quarter EPS, analysts have given the company a lowest target -$1.6 which is -$1.6 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.29 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 16.84% while it is estimated to increase by 53.99% in next year.
